JP2021035361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021035361A5 JP2021035361A5 JP2020163156A JP2020163156A JP2021035361A5 JP 2021035361 A5 JP2021035361 A5 JP 2021035361A5 JP 2020163156 A JP2020163156 A JP 2020163156A JP 2020163156 A JP2020163156 A JP 2020163156A JP 2021035361 A5 JP2021035361 A5 JP 2021035361A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cell
- cancer
- tcr
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 16
- 108091008874 T cell receptors Proteins 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297495P | 2016-02-19 | 2016-02-19 | |
| GB1602918.3 | 2016-02-19 | ||
| GBGB1602918.3A GB201602918D0 (en) | 2016-02-19 | 2016-02-19 | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| US62/297,495 | 2016-02-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540851A Division JP2019513005A (ja) | 2016-02-19 | 2017-02-17 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021035361A JP2021035361A (ja) | 2021-03-04 |
| JP2021035361A5 true JP2021035361A5 (enExample) | 2021-06-10 |
Family
ID=58057145
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020163153A Pending JP2021040627A (ja) | 2016-02-19 | 2020-09-29 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020163154A Pending JP2021040628A (ja) | 2016-02-19 | 2020-09-29 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020163156A Pending JP2021035361A (ja) | 2016-02-19 | 2020-09-29 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020163155A Pending JP2021045124A (ja) | 2016-02-19 | 2020-09-29 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020163153A Pending JP2021040627A (ja) | 2016-02-19 | 2020-09-29 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020163154A Pending JP2021040628A (ja) | 2016-02-19 | 2020-09-29 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020163155A Pending JP2021045124A (ja) | 2016-02-19 | 2020-09-29 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10702592B2 (enExample) |
| JP (4) | JP2021040627A (enExample) |
| CN (1) | CN114028549A (enExample) |
| CL (4) | CL2018002096A1 (enExample) |
| CO (1) | CO2018008239A2 (enExample) |
| MA (1) | MA55153A (enExample) |
| PH (1) | PH12018501639A1 (enExample) |
| ZA (1) | ZA201805512B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210328930A1 (en) * | 2020-01-28 | 2021-10-21 | Intel Corporation | Predictive queue depth |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001000673A1 (en) * | 1999-06-30 | 2001-01-04 | Millennium Pharmaceuticals, Inc. | Membrane-associated and secreted proteins and uses thereof |
| US20050164202A1 (en) * | 2000-02-03 | 2005-07-28 | Emtage Peter C.R. | Materials and methods relating to therapy and diagnosis using targeting of cells that express JPL polypeptides |
| GB2373500B (en) * | 2000-02-04 | 2004-12-15 | Aeomica Inc | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| GB0020953D0 (en) * | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| WO2002083856A2 (en) * | 2001-04-11 | 2002-10-24 | Bristol-Myers Squibb Company | Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof |
| JP2004229507A (ja) | 2003-01-28 | 2004-08-19 | Japan Science & Technology Agency | 転写活性化因子 |
| US20080039413A1 (en) | 2003-10-21 | 2008-02-14 | Morris David W | Novel compositions and methods in cancer |
| WO2010024289A1 (ja) * | 2008-08-27 | 2010-03-04 | シスメックス株式会社 | Il-17産生ヘルパーt細胞検出用マーカー及びil-17産生ヘルパーt細胞の検出方法 |
| KR101458623B1 (ko) * | 2009-09-02 | 2014-11-11 | 조선대학교산학협력단 | 종양 세포-살해 펩타이드 |
| US9410965B2 (en) | 2009-09-17 | 2016-08-09 | Battelle Energy Alliance, Llc | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| EP2806883B1 (en) * | 2012-01-25 | 2019-04-24 | DNAtrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| WO2013169971A1 (en) * | 2012-05-10 | 2013-11-14 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
| CN104662171B (zh) * | 2012-07-12 | 2018-07-13 | 普瑟姆尼股份有限公司 | 个性化癌症疫苗和过继免疫细胞治疗 |
| ES2452485B1 (es) * | 2012-07-13 | 2015-03-09 | Univ Valladolid | Mutantes de apoacuorina y metodos para su uso |
| SI3514172T1 (sl) | 2014-04-01 | 2020-07-31 | Biontech Cell & Gene Therapies Gmbh | Claudin-6 specifični imunoreceptorji in T-celični epitopi |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
-
2017
- 2017-02-17 CN CN202111312815.XA patent/CN114028549A/zh active Pending
- 2017-02-17 MA MA055153A patent/MA55153A/fr unknown
-
2018
- 2018-08-02 PH PH12018501639A patent/PH12018501639A1/en unknown
- 2018-08-03 CO CONC2018/0008239A patent/CO2018008239A2/es unknown
- 2018-08-03 CL CL2018002096A patent/CL2018002096A1/es unknown
- 2018-08-17 ZA ZA2018/05512A patent/ZA201805512B/en unknown
-
2019
- 2019-05-17 US US16/415,552 patent/US10702592B2/en active Active
- 2019-07-03 US US16/502,305 patent/US10702593B2/en active Active
-
2020
- 2020-06-03 US US16/891,940 patent/US10813986B2/en not_active Expired - Fee Related
- 2020-09-29 JP JP2020163153A patent/JP2021040627A/ja active Pending
- 2020-09-29 JP JP2020163154A patent/JP2021040628A/ja active Pending
- 2020-09-29 JP JP2020163156A patent/JP2021035361A/ja active Pending
- 2020-09-29 JP JP2020163155A patent/JP2021045124A/ja active Pending
- 2020-09-30 US US17/039,177 patent/US10933125B2/en not_active Expired - Fee Related
- 2020-11-04 CL CL2020002858A patent/CL2020002858A1/es unknown
- 2020-11-04 CL CL2020002856A patent/CL2020002856A1/es unknown
- 2020-11-04 CL CL2020002857A patent/CL2020002857A1/es unknown
-
2021
- 2021-02-02 US US17/165,457 patent/US20210154284A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513005A5 (enExample) | ||
| JP2020191862A5 (enExample) | ||
| JP2020182458A5 (enExample) | ||
| JP2020198875A5 (enExample) | ||
| JP2021101700A5 (enExample) | ||
| JP2019516663A5 (enExample) | ||
| JP2020506690A5 (enExample) | ||
| JP2024099580A5 (enExample) | ||
| JP2019536426A5 (enExample) | ||
| AR121383A2 (es) | Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres | |
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| HRP20230512T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma | |
| JP2020516681A5 (enExample) | ||
| HRP20210709T1 (hr) | Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma | |
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| HRP20201281T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma | |
| JP2019502360A5 (enExample) | ||
| JP2019520038A5 (enExample) | ||
| FI3388075T3 (fi) | Uusia peptidejä ja peptidien yhdistelmiä käytettäviksi immunoterapiaan erilaisia syöpiä vastaan | |
| JP2020516313A5 (enExample) | ||
| JP2020191873A5 (enExample) | ||
| CN108727470A (zh) | 一种多肽及其应用 | |
| HRP20210528T1 (hr) | Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma | |
| JP2021035361A5 (enExample) | ||
| JP2021040627A5 (enExample) |